Primary endpoint CV deathMIstroke for aspirin vs no aspirin 28 vs 30 p 054 CV death 086 vs 078 p 089 nonfatal cerebrovascular disease 165 vs 164 ID: 932472
Download Presentation The PPT/PDF document "No aspirin (n = 7,335) JPPP" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
No aspirin(n = 7,335)
JPPP
Primary endpoint (CV death/MI/stroke) for aspirin vs. no aspirin: 2.8% vs. 3.0%, p = 0.54 CV death: 0.86% vs. 0.78%, p = 0.89; nonfatal cerebrovascular disease: 1.65% vs. 1.64%, p = 0.78; nonfatal MI: 0.3% vs. 0.6%, p = 0.019; TIA: 0.26% vs. 0.49%, p = 0.044Serious extracranial hemorrhage: 0.86% vs. 0.51%, p = 0.004); intracranial hemorrhage: 0.07% vs. 0.07%
Trial design: Japanese patients with atherosclerotic risk factors were randomized 1:1 to receive enteric-coated aspirin 100 mg once daily or no aspirin in addition to usual care. They were followed for 5 years.
Results
Conclusions
Ikeda Y, et al. JAMA 2014;312:2510-20
Aspirin(n = 7,323)
Primary endpoint
Low-dose enteric-coated aspirin is not superior to no aspirin in reducing CV events as a primary prevention strategy in elderly Japanese subjectsThere were modest reductions in the risk of nonfatal MI and TIA, but this was tempered by an increase in extracranial bleeding including GI bleeding and numerous other GI side effects
%
(
p
= 0.54
)